Stockreport

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance...

EyePoint Pharmaceuticals, Inc.  (EYPT) 
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO [Read more]